Amgen CEO Discusses $1 Billion Investment, Tariffs, and AI in Drug Development

New Manufacturing Investment in Ohio

• 💡 Amgen announced a $1 billion investment to expand its manufacturing capabilities in Columbus, Ohio.
• 🚀 This expansion will create several hundred permanent jobs and increase the total investment in the Columbus facility to $1.5 billion, employing about 750 people.
• 📊 Amgen has invested approximately $5 billion in US manufacturing between 2018 and 2024, generating about $12 billion in incremental economic activity.

Impact of Tariffs on Pharmaceutical Industry

• ⚠️ A potential 25% tariff on US pharmaceutical imports could increase prescription costs by nearly $51 billion annually and raise prices by approximately 13%.
• 🌍 Currently, 73% of US imported pharma products, totaling $23 billion as of 2023, come from Europe (Ireland, Germany, Switzerland).
• 📉 Companies like Merck are already experiencing financial impacts from trade wars, with Merck warning of a $200 million hit and cutting full-year profit expectations.
• 🇺🇸 Amgen's manufacturing base originated in the US, and the 2017 tax reform enabled further domestic investment, though the company remains adaptable to potential tariff changes.

Amgen's Drug Development Pipeline

• 🎯 Amgen is advancing its obesity drug, Maritide, into Phase 3 development, aiming for a monthly injection regimen.
• 🔬 The company is also excited about its pipeline of medicines for cancer, heart disease, autoimmune disorders, and rare diseases.
• 📈 Amgen is leveraging AI and machine learning to identify patients, select optimal trial sites, and choose the right molecules early in the drug discovery process.
• 🤝 Amgen has been an early adopter of AI technology, sourcing capabilities from providers like Nvidia and developing in-house expertise to influence all aspects of its business.